mRNA therapy: the development of an HIV vaccine reduces the risk of infection in rhesus monkeys by 79%

Article source: Medical Rubik's Cube Pro

Author: Haimer

In the COVID-19 pandemic, the development of mRNA vaccines at a record speed has made a huge contribution to the world's fight against the epidemic

An article of research progress published in Nature Medicine on December 9th brings hope to the development of mRNA vaccines to overcome HIV

Research results show that the new mRNA vaccine is safer and can induce both humoral and cellular immune processes

Dr.

The principle of the new HIV vaccine is similar to that of the mRNA new crown vaccine

3 representative Env-GagVLP (Source: Nature Medicine)

Dr.

Experiment with neutralizing antibody levels in rhesus monkeys over time (Source: Nature Medicine)

The research team tested the Env-Gag VLP mRNA vaccine on rhesus monkeys

Induction of Env-specific T cell responses in rhesus monkeys in the experimental group (Source: Nature Medicine)

Experimental results showed that although the injected mRNA dose was very high, the vaccine was well tolerated, and the rhesus monkeys had only mild, temporary side effects

New vaccine can prevent Rhesus monkeys from being infected with SIV (Source: Nature Medicine)

After 13 weeks, 2 of the 7 experimental group animals were uninfected, and the average infection time of other vaccinated rhesus monkeys was delayed by more than 8 weeks; in contrast, the unimmunized rhesus monkeys in the control group averaged after 3 weeks Infection

Although the results of the study are very encouraging, the vaccination protocol in the experiment must be immunized with high doses of mRNA for multiple immunizations

Reference materials:

[1] Peng Zhang et al.

[2] Lynn Morris.

[3] Experimental mRNA HIV vaccine safe, shows promise in animals.